论文部分内容阅读
最近20年来在肝癌的临床方面有显著的进展,本文拟就近20年来肝癌的诊断、治疗方面的现状加以叙述。一、诊断方法的进步1.甲胎蛋白(AFP) 在测定方法上用放射免疫的方法可以进行定量,使得研究工作有显著的进展。据1979年日本全国统计,原发性肝细胞癌病例中有80%呈现阳性。AFP的波动可作为推测临床经过的重要指标,同时又可作为判定化学疗法、肝动脉栓塞疗效的参考,以及估计癌的进展与复发的良好指标。根据著者等的经验在有切除可能的100例肝癌中AFP的阳性率(20ng以上者)
In the recent 20 years, there has been significant progress in the clinical aspects of liver cancer. This article will describe the status of diagnosis and treatment of liver cancer in the past 20 years. First, the progress of diagnostic methods 1. AFP (AFP) can be quantified using radioimmunoassay methods, making the research work has made significant progress. According to the national statistics of Japan in 1979, 80% of cases of primary hepatocellular carcinoma were positive. The fluctuation of AFP can be used as an important indicator to predict the clinical course. At the same time, it can be used as a reference to determine the efficacy of chemotherapy, hepatic artery embolism, and a good indicator of cancer progression and recurrence. According to the author’s experience, the positive rate of AFP in 100 cases of possible resection of liver cancer (20ng or more)